100 participants
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-05
- Start Date:
- 2017-05-18
- Completion:
- 2025-09-11
Conditions
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Ovarian Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Refractory Fallopian Tube Carcinoma
- Refractory Ovarian Carcinoma
- Refractory Primary Peritoneal Carcinoma
Interventions
- BIOLOGICAL